Actualités

Oscar Health (OSCR) is back in focus after reporting second quarter 2026 results that swung from a loss to net income of $361.81 million and raising full year earnings guidance. See our latest analysis for Oscar Health. Oscar Health shares have been volatile around the earnings release, with an 11.9% drop reported after the outlook update. The stock still shows a 118.84% year to date share price return and a 109.46% 1 year total shareholder return, suggesting momentum remains strong despite...

The S&P 500 and Nasdaq look ready to run, but they haven't quite done so. Sandisk surged but must do this. Walmart, Target loom.

MTCH, PBI, and OSCR it to the Zacks Rank #1 (Strong Buy) growth stocks list on August 14, 2026.

MTCH, PBI, and OSCR it to the Zacks Rank #1 (Strong Buy) growth stocks list on August 12, 2026.

Oscar Health reported second-quarter 2026 results showing a shift from a prior-year loss to net income of US$361.81 million and lifted its full-year 2026 guidance to total revenue of US$18.70–US$19.00 billion and earnings from operations of US$500–US$700 million. This combination of a profit turnaround and a sizeable upgrade to operating earnings expectations suggests Oscar’s underlying operations are running more efficiently than previously anticipated. We’ll now examine how Oscar’s...

Oscar Health (OSCR) delivered earnings and revenue surprises of +155.81% and -0.92%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Health insurance company Oscar Health (NYSE:OSCR) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 70.4% year on year to $4.88 billion. Its GAAP profit of $1.10 per share was significantly above analysts’ consensus estimates.

SANM, OSCR and PENN made it to the Zacks Rank #1 (Strong Buy) growth stocks list on August 6th, 2026.

S&P 500 health insurer Centene blew away Q2 earnings forecasts amid lower-than-expected Affordable Care Act Marketplace benefit costs. CNC stock initially moved higher, but shares reversed sharply lower as the company discussed its outlook, including slightly higher Medicaid attrition and a more costly covered population in the second half of 2026. Centene posted Q2 earnings of $2.51 a share, crushing forecasts of $1.09 by $1.42 a share.

Oscar Health (OSCR) has been drawing attention after a strong share price run, with investors weighing that performance against mixed valuation signals that suggest the stock is not an obvious bargain. See our latest analysis for Oscar Health. Recent trading has cooled slightly, with the share price down around 3% over the past month and 7 days. That comes after a strong 90 day share price return of about 68% and a very large 3 year total shareholder return, suggesting momentum has been...

Goosehead (GSHD) delivered earnings and revenue surprises of +23.08% and +9.70%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Solid retention, renewals, prudent pricing, exposure growth and improved digitization are expected to help CINF, RGA, OSCR, WTW and AFL outperform Q2 estimates.

Better pricing, product redesigns and technological advancements are expected to aid Zacks Multiline Insurance industry players like OSCR, RDN, CNO, PLGO and HMN.

Baird said the outcomes from the final 2025 healthcare exchange risk adjustment transfers support Centene’s prior Q4 commentary and align directionally with Oscar’s comments at a June investor conference.

Oscar Health (OSCR) has been back on investors’ radar after a sharp stock rally following its business update at the Goldman Sachs Healthcare Conference, where management reaffirmed full-year 2026 guidance and highlighted favorable utilization trends. See our latest analysis for Oscar Health. The stock’s rally around the Goldman Sachs Healthcare Conference and upbeat commentary on utilization trends come on top of very strong momentum, with a 90 day share price return of 118.52% and a 1 year...

Is OSCR a good stock to buy? We came across a bullish thesis on Oscar Health, Inc. on Deep Value Returns’s Substack. In this article, we will summarize the bulls’ thesis on OSCR. Oscar Health, Inc.’s share was trading at $27.22 as of June 9th. Oscar Health, Inc. operates as a healthcare technology company in the United […]

Capital continued to flow toward companies with visible execution and growth opportunities.

Oscar Health shares rally on a bullish Barclays’ research note. Here’s how high the investment firm believes OSCR stock could fly in 2026.

Oscar Health, Inc. recently amended and restated its employment agreement with co-founder Mario Schlosser as he moved from President of Technology and Chief Technology Officer to Co-Founder & Advisor to the CEO, effective June 1, 2026, while he continues to support the company’s artificial intelligence and digital health agenda and remains on the Board. At the same time, a major Wall Street firm upgraded its view on Oscar Health after Q1 2026 results exceeded expectations and reinforced...

Wells Fargo raises price target on Oscar Health stock to $20. Here’s why the bank turned bullish on OSCR shares.

Broadcom downgraded, UnitedHealth upgraded: Wall Street's top analyst calls

Oscar Health’s tech-driven growth contrasts with UnitedHealth’s massive scale and diversified revenue.

Investors are still underappreciating the potential for this healthcare company's growth.

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.

Oscar Health stock hasn't looked back after reporting Q1 earnings that more than doubled from the year-ago quarter.

Shareholders of Oscar Health, Inc. ( NYSE:OSCR ) will be pleased this week, given that the stock price is up 13% to...

Oscar Health (NYSE:OSCR) surged nearly 11% in premarket trading on Wednesday after the company reported first-quarter earnings far above Wall Street expectations, driven by strong profitability gains and improving operating margins. The health insurance provider posted adjusted earnings per share of $2.

Oscar Health (OSCR) delivered earnings and revenue surprises of +71.07% and -5.02%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?